Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer's Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 Am...
Axsome Therapeutics, Inc. (AXSM)
Last axsome therapeutics, inc. earnings: 3/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
axsome.com
Company Research
Source: Yahoo! Finance
Presentation featuring network meta-analysis of SYMBRAVO ® versus oral CGRPs NEW YORK, April 04, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced multiple presentations spanning its innovative, industry-leading psychiatry and neurology portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting, being held April 5-9 in San Diego, California. Oral and poster presentations include data from the positive pivotal ACCORD-2 Phase 3 trial of AXS-05 in Alzheimer's disease (AD) agitation, accepted as a late-breaking abstract, and from the positive pivotal SYMPHONY Phase 3 trial of AXS-12 in narcolepsy. Additional data being presented includes a network meta-analysis comparing the efficacy of SYMBRAVO ® (AXS-07) to oral CGRPs in the acute treatment of migraine. Details for the presentations are as follows: Alzheimer's Disease Agitation
Show less
Read more
Impact Snapshot
Event Time:
AXSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AXSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AXSM alerts
High impacting Axsome Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AXSM
News
- Axsome Therapeutics (AXSM): Evaluating Valuation Following Recent Share Price Momentum and Pipeline Expansion [Yahoo! Finance]Yahoo! Finance
- Axsome Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire
- Pomerantz LLP and The Rosen Law Firm, P.A. Announce Proposed Class Action Settlement on Behalf of Purchasers of Axsome Therapeutics, Inc. Common Stock - AXSMGlobeNewswire
- 2 Monster Stocks in the Making [Yahoo! Finance]Yahoo! Finance
- Axsome Therapeutics, Inc. (NASDAQ:AXSM) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year [Yahoo! Finance]Yahoo! Finance
AXSM
Earnings
- 11/3/25 - Miss
AXSM
Sec Filings
- 12/4/25 - Form 4
- 12/4/25 - Form 144
- 12/3/25 - Form 144
- AXSM's page on the SEC website